Norfloxacin 400MG + Tinidazole 600MG Tablets contain two separate API's within one solid oral dose at high strength. For a formulation perspective, particular attention needs to be given to powder attributes, API distribution, compression and separation for analysis as both the APIs comprise a large percentage of the final tablet. Norfloxacin 400MG Tindiazole 600MG Tablets can be used as part of a PCD Pharma Franchise product range within a structured pharma franchise portfolio supported by tight manufacturing and quality control procedures.
The above combined active load also affects tablet size, powder flow, lubricating requirements, and compression parameters. The goal of formulation development is to design a workable tablet structure with uniform content and unvarying finished-product properties.
Formulation Development The formulation development begins with the characterization of free norfloxacin and free tinidazole as the individual API's. Particle size, bulk density, flowability, moisture content and interactions with the given excipients, are taken into account prior to establishing the manufacturing process.
With 400MG of norfloxacin and 600MG of tinidazole in the formulation, the active ingredients are significant weight components of the total tablet. The excipients must be chosen appropriately to achieve flow, binding, lubrication and compression properties without significantly increasing the size of the tablet.
Raw materials are dosed as per the approved formulation specification The weighing is accurate and evidenced by the correct identification because at any point in the process both active ingredients must stay within the defined limits.
The measurement of compatibility is also part of product development. Here, the active substances and excipient system are investigated to determine appropriate processing conditions to ensure that the physical properties of the blend are preserved.
Due to high active loading, the handling of powder and mixing behavior may be affected. The disparity in particle size and density between norfloxacin and tinidazole may result in problems associated with segregation.
The formulation may thus require controlled sieving, pre-blending or other appropriate powder-conditioning steps prior to final blending. The sequence of addition can be decided on the physical properties of the individual components.
Mixing parameters (blending time, equipment loading and transfer conditions) are maintained according to established manufacturing process. The aim is to achieve a homogenous mixture prior to compression.
Sample splits can be obtained from various points in the blend and tested for the active ingredient. These tests tell whether the high-load formulation is sufficiently uniform before it enters the tablet press.
Transfer rate: Controlled transfer rate is one of the effectiveness as too much vibrations or standing movement during blend can have an impact on the distribution of powders.
The formulation is then compressed into the final tablet shape once the blend has achieved the desired processing qualities. The high active content means that compression optimization is a critical process.
For each formulation the compression force, machine speed, tooling setup and powder-feed characteristics are determined to give tablets of the required dimensions and with adequate mechanical strength. The formulation needs to be robust enough to withstand handling and packing without exceeding the necessary dissolution and disintegration.
Checks during the process may include weight, tablet thickness, hardness, friability and appearance. They can help control the quality of the tablets being manufactured throughout the batch.
Once the tablets are completed they are dedusted and visually inspected prior to packaging. Tablets which have defects like capping, lamination, sticking or damages on the edges can be identified by suitable inspection procedures.
The assay of a dual active system necessarily involves the individual assay of the norfloxacin and tinidazole. Analytical methods are either a) readied or b) established that are appropriate for the detection and quantification of each active pharmaceutical constituent in the combined tablet formulation.
Finished-product testing may be done for identity, assay, dissolution, disintegration, uniformity, average weight and friability as specified in the approved specification. Dissolution testing is especially important when for a combination tablet having two separate components for release characteristics.
Analytical techniques should give reproducible separation of the two components and be sufficiently precise for quantitative testing. Samples are taken from the manufacturing batch to be representative of the laboratory batch.
Quality documents include raw-material documents, dispensing records, blend-process data, compression documents, and laboratory data. It is from the documents in question that traceability can be assured for the production process and review of each batch can be systematically performed.
Stability: The following tests are carried out to check the stability of Norfloxacin 400MG + Tinidazole 600MG Tablets against storage. Assay, dissolution, appearance and tablet integrity are studied according to a specific schedule at a predefined temperature.
Packaging choices are an aspect of stability planning. Consider the use of blister packs, strips and other appropriate packaging formats for the pharmaceutical to meet its environmental protection needs.
The material that is chosen for the packaging should offer effective protection from the environment as well as moisture while in transit and storage from one location to another so that the tablets are preserved. Packaging for the seal, suitability of the material and labels are taken into account.
As a pharmaceutical company expanding your product range, Norfloxacin 400MG + Tinidazole 600MG Tablets can be added to a well-organized PCD Pharma Franchise range. With assured high-capacity blending, optimized compression, assured analytical testing and correct protective packaging, an average quality product can be provided.
Overall, the combination tablet manufacturing process encompasses: active-material characterization high-dose powder processing and blend uniformity compression optimization dissolution testing analytical validation stability studies and package compatibility. Controlled conditions maintained throughout the process ensure reproducible manufacturing and high-quality finished-products.
Norfloxacin 400mg + Tinidazole 600mg Tablets covering formulation, manufacturing, quality testing, stability, packaging and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech